US20010051186A1 - Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity - Google Patents

Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity Download PDF

Info

Publication number
US20010051186A1
US20010051186A1 US09/774,271 US77427101A US2001051186A1 US 20010051186 A1 US20010051186 A1 US 20010051186A1 US 77427101 A US77427101 A US 77427101A US 2001051186 A1 US2001051186 A1 US 2001051186A1
Authority
US
United States
Prior art keywords
mucoadhesive
layer
active substance
weight
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/774,271
Inventor
Ramesh Acharya
Joseph Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/774,271 priority Critical patent/US20010051186A1/en
Publication of US20010051186A1 publication Critical patent/US20010051186A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Definitions

  • This invention relates to a composition and a method for oral transmucosal delivery of active substances to a human or animal via the inner buccal cavity. More particularly, this invention relates to an improved dosage form which can easily adhere to the inner buccal cavity and sustain transmucosal release of drugs, odorants or any other ingredients and exhibit the activity effectively.
  • drugs administered through the buccal and sublingual routes have a rapid onset of action, reach high levels in the blood, avoid the first-pass effect of hepatic metabolism, and avoid exposure of the drug to fluids of the gastrointestinal tract. Additional advantages include easy access to the membrane sites so that an active substance containing device can be applied, localized, and removed easily. Further, there is good potential for prolonged delivery through the mucosal membrane. M. Rathbone & J. Hadgraft, 74 Int'l J. of Pharmaceutics 9 (1991).
  • the sublingual mucosa includes the membrane of the ventral surface of the tongue and the floor of the mouth, whereas the buccal mucosa constitutes the lining of the cheek.
  • the sublingual mucosa is relatively more permeable than the buccal mucosa, thus giving rapid absorption and acceptable bioavailability of many active substances.
  • the sublingual mucosa is convenient, accessible, and generally well accepted. This route has been investigated clinically for the delivery of a substantial number of drugs. It is the preferred route for administration of nitroglycerin and is also used for buprenorphine and nifedipine. D. Harris & J. Robinson, 81 J. Pharmaceutical Sci. 1 (1992).
  • the buccal mucosa is less permeable than the sublingual mucosa.
  • the rapid absorption and high bioavailabilities seen with sublingual administration of drugs is not generally provided to the same extent by the buccal mucosa.
  • the permeability of the oral mucosa is probably related to the physical characteristics of the tissues.
  • the sublingual mucosa is thinner than the buccal mucosa, thus permeability is greater for the sublingual tissue.
  • the palatal mucosa is intermediate in thickness, but is keratinized thus lessening its permeability, whereas the other two tissues are not.
  • a device containing an active substance within a mucosal-lined body cavity, such as the oral cavity.
  • a mucosal-lined body cavity such as the oral cavity.
  • conventional forms of substance delivery such as a lozenge, troche, breath freshener, mouth wash or spray work by shedding or admixing the substance into the saliva, which bathes the tissues of the oral cavity and throat as it passes posteriorly towards the esophagus.
  • Such forms remain in the oral cavity only for short periods of time, generally not more than about 10 to 20 minutes, and they cannot always provide for effective sustained delivery of the substance.
  • lozenge or troche in the user's mouth can be annoying or distracting, and may interfere with speech or with the ingestion of fluids. Holding the lozenge in the mouth to avoid either swallowing it or spitting it out requires conscious effort, and inadvertent loss can be embarrassing.
  • these adhesives consist of a matrix of a hydrophilic, e.g., water soluble or swellable, polymer or mixture of polymers which can adhere to wet mucosal surfaces.
  • a hydrophilic e.g., water soluble or swellable, polymer or mixture of polymers which can adhere to wet mucosal surfaces.
  • Such polymers are inclusive of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxy ethylcellulose, ethylcellulose, carboxymethyl cellulose, dextran, gaur-gum, polyvinyl pyrrolidone, pectins, starches, gelatin, casein, acrylic acid, acrylic acid esters, acrylic acid copolymers, vinyl polymers, vinyl copolymers, vinyl alcohols, alkoxy polymers, polyethylene oxide polymers, polyethers, and the like.
  • These adhesives may be formulated as ointments, thin films, tablets, troches, and other forms. Often, these
  • sodium alginate is also an anionic polymer that shows ionic interaction with cationic active substances. Therefore, to formulate an adhesive having little or no interaction with ionic active substances, such as ionic polypeptide based drugs, would be highly desirable.
  • PVP polyvinyl pyrrolidone
  • a plasticizer used alone or in combination with other polymers or copolymers
  • PVP polyvinyl pyrrolidone
  • a plasticizer used alone or in combination with other polymers or copolymers
  • PVP is a non-ionic compound
  • PVP-based mocoadhesive does not interact with ionic active substances.
  • PVP-based adhesives show a significant reduction in irritation of mucosa in human trials, compared to Carbopol-based adhesives.
  • plasticized PVP has been used as an ingredient of bioadhesive compositions in prior art
  • a non-plasticized PVP based mucoadhesive has not heretofore been taught or suggested.
  • the non-plasticized PVP based mucoadhesives of this invention show an improved stability when compared with prior mucoadhesives.
  • U.S. Pat. No. 4,740,365 discloses a sustained-release mucoadhesive preparation that may consist of one or two layers.
  • the mucoadhesive layer is always a combination of two polymers components with a ratio of 95:5 to 5:95.
  • One polymer component comprises one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether.
  • the other polymer component comprises one or more polymers selected from polyacrylic acid or a salt thereof.
  • One aspect of the invention is to combine the two polymer components to maximize adhesive properties.
  • 5,700,478 discloses a water-soluble pressure-sensitive adhesive including a water-soluble polymer that is made tacky at room temperature by addition of a water-soluble plasticizer that is miscible with the polymer.
  • the presence of the plasticizer negatively affects the palatability and stability of the mucoadhesive.
  • the presence of plasticizers or other ionic polymers in the mucoadhesive may also cause undesirable wearing properties or irritation.
  • the non-plasticized PVP-based mucoadhesive of the present invention also simplifies and reduces the cost of manufacture.
  • a non-plasticized PVP-based mucoadhesive of this invention also reduces the unpleasant flavor and oral irritation associated with plasticizers or other copolymers.
  • a laminated active substances delivery device comprising a layer of mucoadhesive composition consisting primarily of PVP without a plasticizer.
  • the non-plasticized PVP mucoadhesives of this invention can adhere to the inner buccal cavity or palate for delivering both charged and non-charged active substances.
  • Such non-plasticized PVP mucoadhesives provide for localization of the active substance-containing delivery device over a sustained period to maximize drug effect and then dissolve in the secretions present in the buccal cavities without having an objectionable taste or causing irritation.
  • the non-plasticized PVP mucoadhesive has sufficient adhesion not only to mucosal membranes but also to a variety of materials, such as polyacrylic denture material.
  • This invention therefore provides dosage forms having an adhesive surface suitable for affixing to the mucosal surface of the inner buccal cavity.
  • the non-plasticized PVP mucoadhesive serves as a reservoir for the substances to be delivered, and releases the substances into the oral cavity as the adhesive dissolves.
  • the active substance absorption also occurs via diffusion of the active substance through the adhesive layer of the device into the mucosal membrane.
  • a laminated device includes at least one active polymer layer in addition to the base mucoadhesive layer. Each layer may release one or more substances according to a desired timed delivery regime, for example, delayed onset delivery, pulsed delivery, and sequential delivery.
  • the invention is particularly useful to deliver ionic active substance because the non-plasticized PVP mucoadhesives do not interact with ionic active substances and to the delivery of active substances intended for use directly in the oral cavity such as breath fresheners and saliva enhancing agents.
  • the invention is uniquely suited to the delivery of breath freshening agents to the oral cavity particularly when the mucoadhesive layer is adhered to the hard palate or roof of the mouth.
  • Active substance refers to all functional compounds which are desirable to be delivered via oral cavity, either charged or non-charged, including but not limited to, medicaments for oral diseases, diseases of the teeth and also systemic diseases, oral odorants such as breath freshening agents, saliva stimulants, nutritional supplements such as vitamins, herb extracts or minerals, and mixtures thereof.
  • oral odorants such as breath freshening agents, saliva stimulants, nutritional supplements such as vitamins, herb extracts or minerals, and mixtures thereof.
  • odorants suitable for masking or refreshing objectionable breath including peppermint, spearmint, menthol, grape, cherry, lemon, strawberry, orange, licorice, lime and any mixtures thereof.
  • Active substances to be delivered by the device of the present invention includes ionic or non-ionic drugs for oral or systemic diseases, for example, peptide drugs (e.g.
  • calcitonin, DDAVP analgesics and antiinflammatory agents
  • e.g. indomethacin, ibuproden mouth disinfectants
  • chlorohexidine hydrochloride, hexylresorcine cardiovascular agents
  • antiasthmatics e.g. disodium cromoglycate
  • antibiotics e.g. penicillin, erythromycin
  • chemotherapeutics e.g. sulfathiazole, nitrofurazone
  • local anesthetics e.g. benzocaine
  • cardiotonics e.g.
  • “Mucoadhesive,” refers to hydrophilic polymers, natural or synthetic, which, by the hydrophilic designation, can be either water soluble or swellable and which are adhesive to mucosal surfaces.
  • adhesives adhere the active substances-containing formulation to the mucosal tissues as well as functioning as a reservoir of active substances which can be dissolved or absorbed via contacting the mucosal membrane.
  • PVP polyvinylpyrrolidone
  • PVP mucoadhesive non-plasticized PVP mucoadhesive
  • non-plasticized PVP mucoadhesive refers to a mucoadhesive composition consisting essentially of PVP polymer that does not contain any plasticizers.
  • Polyvinylpyrrolidone is a homopolymer of 1-ethenyl-2pyrrolidinone and is available in various grades under the generic or tradename “Povidone”. Mixtures of one or more grades or molecular weights of PVP polymers may be utilized.
  • PVP polymers will have an average molecular weight of between about 10,000 and 700,000.
  • hydrophilic ionic or nonionic polymers or copolymers conventionally used in adhesive formulations may be combined with the nonplasticized PVP depending on use. If the substance to be delivered is nonionic it may not be disadvantageous to utilize some ionic polymers or copolymers. On the other hand, when delivering an ionic substance, it is preferred that an added hydrophilic polymer be nonionic.
  • hydrophilic polymers or copolymers that may be combined with PVP include acrylic acid polymers, e.g. carboxyvinyl or carboxymethylene polymers such as sold under the generic of tradenames “Carbomer” and “Carbopol”; hydroxypropyl cellulose such as sold under the tradename “Klucel”; methylcellulose such as sold under the tradename “Methocel” and polyethylene oxide polymers such as sold under the tradename “Polyox”.
  • acrylic acid polymers e.g. carboxyvinyl or carboxymethylene polymers such as sold under the generic of tradenames “Carbomer” and “Carbopol”
  • hydroxypropyl cellulose such as sold under the tradename “Klucel”
  • methylcellulose such as sold under the tradename “Methocel”
  • polyethylene oxide polymers such as sold under the tradename “Polyox”.
  • Permeation enhancer means a material that achieves such permeation enhancement
  • an “effective amount” of an enhancer means an amount effective to enhance penetration through the mucosa of a selected agent to a selected degree.
  • Taurocholic acid and its salts are exemplary of transmucosal enhancers.
  • This invention features a laminated active substance delivery system which includes at least one active substance containing polymer layer in addition to a mucoadhesive polymer layer which may also contain active substances.
  • the system releases one or more substances according to a desired time delivery regime. For example, onset of release may be delayed following placement of the delivery system within the body cavity, or a substance may be released at different rates over time, or in pulses with intervening periods in which essentially no release occurs. Alternatively, two or more substances may be sequentially released, with or without an intervening period in which no substance is released. The pattern of release is established by the sequential arrangement of laminates containing the substances, and the concentration of the substances contained in the various layers.
  • the mucoadhesive composition of this invention consists primarily of nonplasticized PVP.
  • the mucoadhesive can be 100% PVP.
  • the ratio of PVP to such other polymers or copolymers will be at least 1:1 and will be preferably between 1:1 and 20:1.
  • nonplasticized PVP will make up between about 50 to 95% by weight of the mucoadhesive composition with the remaining 5 to 50% by weight being a functionally suitable polymer or copolymer.
  • the mucoadhesive composition will make up between about 20-99% by weight of the adhesive layer the with remaining 1 to 80% by weight being a member selected from the group consisting of water soluble compounding agents and any active substances added to the adhesive layer.
  • compounding agents is meant inert ingredients or formulation aids such as lactose, mannitol, magnesium stearate, flavoring agents, coloring agents, stabilizers, binding agents, or any other fillers which do not have a negative impact on the function of the mucoadhesive layer.
  • the non-plasticized PVP mucoadhesives are fully water-soluble, and are thus fully soluble in secretions present in oral mucosa without having an objectionable taste or causing sustained irritation.
  • the non-plasticized PVP mucoadhesives are nonionized and thus are particularly useful to affix a transmucosal delivery formulation for ionic active substances such as polypeptide drugs.
  • the mucoadhesives of this invention can be used to affix any oral delivery device within the oral cavity, e.g. patches, tablets, and the like. It is particularly useful in construction of a laminated or multi-layered device for controlled delivery of substances within the oral cavity.
  • the non-plasticized PVP mucoadhesive layer can serve as a reservoir for the active substances to be delivered, and releases the substance into the oral cavity as the adhesive dissolves.
  • the substances can also be transmucosally absorbed through the adhesive layer which is in contact with an oral mucosal membrane.
  • the release rate of an active substance from a particular layer is determined basically by the rate at which the layer dissolves or disperses in the fluid milieu of the oral cavity, and by the diffusion rate of the active substance from particular layer which is dependent upon the concentration of the active substances within the layer. Release from a more basally situated layer may be delayed by an overlaying layer(s), and the duration of the delay in delivery from such a particular layer is determined basically by the time required for the overlaying layer(s) to disperse.
  • the active substances contained in the adhesive layer can also be absorbed via the contacting mucosal membrane and the absorption may be enhanced by addition of a suitable penetration enhancer into the formulation of either the adhesive layer or an active or overlying layer or both.
  • concentration of the active substance will be an “effective amount,” which is the amount required to achieve the desired delivery either into the oral cavity and/or across mucosal tissues at a rate and for a time which will achieve the desired physiological effect. Those concentrations can be readily determined by the practitioner based upon the active substance selected.
  • active substance concentration in the mucoadhesive layer which may provide “effective amounts,” it is readily apparent that the active substance concentration will, of necessity, be determined by the active substance being utilized and its potency and/or bioavailability. For example, when the active substance is a drug an effective amount will be much smaller than when the active substance is a breath freshener. Effective amounts of an active drug substance may be as little as 0.1% and may be as much as 10% of the mucoadhesive layer. Preferably amounts will be between about 0.2 and 5.0% by weight. On the other hand, effective amounts of breath fresheners vary from about 10 to 60% by weight of the mucoadhesive layer with amounts of between about 20 and 50% being preferred.
  • the pressure-sensitive mucoadhesive composition of the mucoadhesive layer consists essentially of nonplasticized PVP or a combination of PVP and suitable polymers or copolymers.
  • concentration of mucoadhesive in the layer will be between about 20 and 99% by weight.
  • the mucoadhesive concentration is between about 30 and 80%.
  • the remaining amounts are made up from one or more members selected from the group consisting of water soluble compounding agents and any active substances.
  • Such compositions show sufficient adhesion to oral mucosal surfaces of animals such dogs and also to humans and to denture materials.
  • the non-plasticized PVP mucoadhesives of this invention are water soluble, and are capable of conforming to and adhering to contoured surfaces such as the gums, the roof of the mouth and buccal lining of the mouth.
  • Such mucoadhesives can be used as part of a system for delivery of substances through the oral mucosa (as a buccal transmucosal patch), for delivery of substances into the oral cavity itself, or the combination of both via a laminated configuration, which may be either in the form of a tablet or patch.
  • Both patches and tablets are prepared such that the mucoadhesive layer contains the non-plasticized PVP adhesive which may or may not contain a drug/enhancer, while the other layer(s) is non-adhesive, at least on the outer surface, and contains one or more drugs/enhancer combinations, breath fresheners or other active substances.
  • One preferred embodiment of this invention features a layered composite for delivery of an active substance into the oral cavity, having an outer active layer that includes the active substances dispersed or dissolved in a water soluble polymer, and the above-described water soluble mucoadhesive layer. Also as noted above, the rate of release of the active substance within the oral cavity depends partially on the rate of dissolution or dispersion of the polymer of the active layer. As previously mentioned, active substances may also be included in the adhesive layer which may be released with the dissolution of the adhesive layer, and be absorbed by the contacting mucosal membrane as well.
  • the active or outer layer of a bilayer or multilayer system is laminated to the mucoadhesive layer by conventional techniques.
  • the active layer is also based on the presence of a water soluble polymer in which is dispersed the active substance to be delivered along with other compounding agents such as referenced above.
  • the water soluble polymer will be present in amounts of between about 3 and 60% by weight of such hydrophilic polymers or copolymers.
  • hydrophilic polymers or copolymers that may be used in the active layer include those mentioned above for use in the mucoadhesive layer such as acrylic acid polymers, hydroxypropyl cellulose, methylcellulose, polyethylene oxide and polyvinyl pyrrolidone, as well as natural polymers such as gaur-gum, pectins, starches, gelatin, casein and the like.
  • These water soluble polymers are compatible with the active substances to be delivered.
  • such polymers are selected to promote desired active substance release profiles and do not adversely affect the activity of such substance.
  • the active or overlying layer(s) will contain an “effective amount” of the active substance being delivered.
  • the effective amount of active substance will be determined by the active substance being utilized and its potency and/or bioavailability. Those amounts may be the same as in the mucoadhesive layer but may be higher when the mucoadhesive layer is utilized primarily to secure a device to the oral mucosa.
  • the active substance is a drug an effective amount will be much smaller than when the active substance is a breath freshener.
  • Effective amounts of an active drug substance may be as little as 0.1% and may be as much as 10% of the mucoadhesive layer. Preferably amounts will be between about 0.2 and 5.0% by weight.
  • effective amounts of breath fresheners vary from about 1 to 60% by weight of the mucoadhesive layer with amounts of between about 5 and 40% being preferred.
  • the active layer may also contain from between about 40 and 99.9% by weight of compounding agents as defined above.
  • the active substance delivery system of this invention is particularly useful for administering a substance over an extended time period for relief of oral symptoms such as bad breath, sore throat, cough, dry mouth or other similar symptoms.
  • odorants suitable for masking or refreshing objectionable breath include agents such as mint, spearmint, menthol, grape, cherry, lemon, strawberry, orange, licorice, peppermint, lime and any mixtures thereof.
  • Other substances which are suitable for being transmucosally administered by the delivery system of this invention include but are not limited to saliva stimulants, nutritional supplements such as vitamins, herb extracts or minerals, and mixtures thereof.
  • the device of the present invention is also suitable for transmucosally delivery of both ionic or non-ionic drugs for oral or systemic diseases including analgesics and anti-inflammatory agents (e.g. indomethacin, ibuproden), mouth disinfectants (chlorohexidine hydrochloride, hexylresorcine), enzymes (e.g. nitroglycerin, isosorbide dinitrate, nifedipine), antiasthmatics (e.g. disodium cromoglycate), antibiotics (e.g. penicillin, erythromycin), chemotherapeutics (e.g.
  • analgesics and anti-inflammatory agents e.g. indomethacin, ibuproden
  • mouth disinfectants chlorohexidine hydrochloride, hexylresorcine
  • enzymes e.g. nitroglycerin, isosorbide dinitrate, nifedipine
  • antiasthmatics
  • sulfathiazole nitrofurazone
  • local anesthetics e.g. benzocaine
  • cardiotonics e.g. digitalis, digoxin
  • antitussives and expectorants e.g. codeine phosphate, isoproterenol hydrochloride
  • agents affecting digestive organs antihistamines, antiinflammatory steroids, hemostatics, sex hormones, sedatives, antitumor agents, or the like.
  • Effective amounts, i.e. from 2 to 20% by weight, of penetration enhancers such as a salt of a conjugate of a bile acid with taurine or taurocholic acid may be optionally added in the active layer to enhance the penetration of the active drug.
  • the most preferred embodiment of this invention features a laminated device for administering an active agent into the oral cavity over an extended period of time and having the device dissolve without leaving an objectionable taste or cause-sustained irritation to the oral cavity.
  • the device can be either a laminated film or tablet, having at least two layers, including a basal layer of a pressure-sensitive, water-soluble, non-plasticized PVP mucoadhesive composition, which may or may not contain an active agent, and an active agent containing water soluble polymer layer.
  • the device is affixed to the mucosal surface, preferably the palatine surface of the oral cavity via the mucoadhesive layer of the device.
  • the systems utilized in the present invention comprise an active layer containing the active substances and a basal mucoadhesive layer which may also contain an active substance.
  • the systems may be in either the form of a tablet or a patch.
  • Bilayer tablets are made by classical bilayer tablet compression techniques on a suitable press. Layers of a bilayer tablets consisting of an active non-adhesive layer and an adhesive layer may contain layers which are of different colors to distinguish the layers for purposes of application. The identification of the active non-adhesive layer facilitates application by the patient and prevents incidental adhesion of other oral tissues to the tablet.
  • the active layer is prepared by dry mixing the ingredients and compressing them into a tablet or by wet granulating the ingredient mixture and then compressing according to accepted pharmaceutical techniques. In general, it has been found suitable to mix the active substances, polymer and any formulation aids such as magnesium stearate, lactose, flavors, and the like and then compress the mix in a press at about 0.2-0.5 tons for a dwell time of 2-10 seconds.
  • the adhesive layer is first prepared by intimately admixing PVP, copolymers, and tableting excipients and binding compounds such as sorbitol, dyes, flavors, magnesium stearate, mannitol and the like. This may be formulated as a dry mix or accomplished by conventional wet granulation and screening techniques followed by drying. In either event, the blended adhesive layer ingredients are then placed on top of the partially compressed active layer and both layers are then compressed at a higher pressure, for example from 0.5 to 1.5 tons for an additional 2-10 seconds dwell time.
  • the active substance is an odorant such as an essential oil of a plant material, a refined fraction of an essential oil, or a combination of the chief aromatic constituents of an essential oil.
  • the odorant is a mint such as obtained from oils of peppermint, spearmint or wintergreen. Any other suitable odorant or masking agent may also be used such as menthol, grape, cherry, lemon, strawberry, orange, licorice, lime and any mixtures thereof.
  • the active substances may be saliva stimulants, or nutritional supplements such as vitamins, herb extracts or minerals, and mixtures thereof.
  • the systems of the present invention will preferably be sized to provide a device having a contact surface area of between about 0.5 to 10 cm 2 for adhering the the adhesive layer and the mucosal surface. Areas of between about 0.5 to 5 cm 2 are preferred with areas of between about 1.0 and 5 cm 2 being optimal.
  • the active mucoadhesive layers will generally have a thickness of between about 0.1 and 3 mm with thicknesses of between about 0.5 and 2 mm being preferred.
  • Extended delivery of active substances can be obtained according to the bilayered or multilayered device according to the present invention.
  • the rate of release of the active substances within the oral cavity can be specified by selection of particular polymer or polymer combinations.
  • the device according to the present invention is capable of adhering to contoured surfaces such as the gum or the roof of the mouth.
  • the device can deliver the active substances over a period of up to 2 hours or longer from a single device, and can dissolve without leaving any bad taste or causing sustained irritation.
  • the device according to this invention is particularly useful in delivering charged drugs such as polypeptide based drugs because the PVP mucoadhesive is non-ionic which does not interact with ionic drugs to be delivered. Further, the device is particularly adaptable for the delivery of odorants or other active agents for the treatment of halitosis or dryness of the mouth.
  • bilayered breath freshener tablets are prepared in the following manner containing the designated ingredients within the ranges specified.
  • An active layer is prepared by transferring the specified amounts of the following ingredients into a V blender Weight Percentage Ingredients Range (%) Mint Powder 1-80 co-polymer 5-70 Sweetener 0.1-20 Magnesium Stearate 0.1-10 Mannitol 0-80 Dye 0.1-0.8
  • An adhesive layer is prepared by transferring the specified amounts of the following ingredients into a V blender: Weight Percentage Ingredients Range(%) Mint Powder 1-80 PVP 20-90 Carbopol 0-4.8 co-polymer 0-80 Sweetener 0.1-20 Mannitol 0-80
  • the blended materials are then discharged into a suitable container.
  • the adhesive layer blend is then passed through the Fitzmill using the specified screen.
  • the specific amount of magnesium stearate is calculated based on the yield of the adhesive layer blend (0.5-10% by weight), and then added to the blender and blended for a specified amount of time.
  • the final blended materials are collected into tared polyethylene lined containers.
  • the tablet press was set up for bi-layered operation using the specified parameters.
  • the final blended powder for the active layer granulation was placed in the first hopper and the adhesive granulation was placed into the second hopper.
  • the tablet press was set to a specified amount of active layer prior to introducing the specified amount of the adhesive granulation.
  • the compressed tablets were packaged into bottles and labeled with the proper information.
  • This example illustrates a bilayer oral transmucosal tablet for rapid onset delivery of drugs formulated according to the method described in Example 1.
  • the drug to be delivered in this example is Buprenorphine HCL and the penetration enhancer is taurocholic cid.
  • the adhesive layer contains 60% non-plasticized PVP.
  • This example illustrate a bilayer oral transmucosal tablet for long acting delivery of drugs formulated according to the method described in Example 1.
  • the active substance in this example is Buprenorphine HCL, the penetration enhancer is taurocholic acid.
  • the adhesive layer contains 60% non-plasticized PVP and 10% of an acrylic copolymer.
  • This example illustrate a bilayer oral transmucosal tablet for rapid onset delivery of drugs formulated according to the method described in Example 1.
  • the active substance in this example is Fentanyl Citrate, the penetration enhancer is taurocholic acid.
  • the adhesive layer contains 70% non-plasticized PVP.
  • This example illustrate a bilayer oral transmucosal tablet for long acting delivery of drugs formulated according to the method described in Example 1.
  • the active substance in this example is Fentanyl Citrate, the penetration enhancer is taurocholic acid.
  • the adhesive layer contains about 70% non-plasticized PVP and 20% copolymer.
  • This example illustrate a bilayer oral transmucosal tablet for delivery of drugs formulated according to the method described in Example 1.
  • the active substance in this example is DDAVP
  • the penetration enhancer is taurocholic acid.
  • the adhesive layer contains about 70% non-plasticized PVP and 5% of an acrylic copolymer.
  • This example illustrate a bilayer oral transmucosal tablet for delivery of drugs formulated according to the method described in Example 1.
  • the active substance in this example is calcitonin, the penetration enhancer is taurocholic acid.
  • the adhesive layer contains about 30% non-plasticized PVP and 20% of an acrylic copolymer.
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening formulated according to the method described in Example 1.
  • the active substance in this example is menthol mint (50% by weight in active the layer and 30% by weight in the adhesive layer).
  • the adhesive layer contains about 35% non-plasticized PVP.
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening formulated according to the method described in Example 1.
  • the active substance in this example is licorice (20% by weight in the active layer and 30% by weight in the adhesive layer).
  • the adhesive layer contains about 50% non-plasticized PVP.
  • This example illustrate a bilayer oral transmucosal tablet for long acting breath refreshening formulated according to the method described in Example 1.
  • the active substance in this example is menthol mint (40% by weight in the active layer and 30% by weight in the adhesive layer).
  • the adhesive layer contains about 40% non-plasticized PVP and 15% copolymer.
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening and dry mouth relief formulated according to the method described in Example 1.
  • the active substances in this example are eucalyptus oil in the active layer and spearmint in the adhesive layer.
  • the adhesive layer contains a polymer combination of about 20% non-plasticized PVP and 15% copolymer.
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening and dry mouth relief formulated according to the method described in Example 1.
  • the active substances in this example is peppermint (40% by weight in the active layer and 30% by weight in the adhesive layer).
  • the adhesive layer contains about 35% non-plasticized PVP.
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening and dry mouth relief formulated according to the method described in Example 1.
  • the active substances in this example is spearmint (30% by weight in the active layer and 30% by weight in the adhesive layer).
  • the adhesive layer contains about 20% non-plasticized PVP and 15% copolymer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

A device and method for the oral transmucosal delivery of active substances to the oral cavity utilizing an unplasticized polyvinyl pyrrolidone polymer (PVP) as the primary mucoadhesive. The device is applied and adheres to the mucosa of the oral cavity without causing side effects or leaving an unpleasant taste. Preferably the device is a bilayer tablet having a mucoadhesive layer and an overlying active substance containing layer. The mucoadhesive layer may contain PVP as the only adhesive or may be combined with other hydrophilic polymeric substances. The active layer also contains a hydrophilic polymer carrier. The layers in the device dissolve and release the active substance to the oral cavity and is particularly adapted for the delivery of substances active in the oral cavity such as breath fresheners and substances to combat dry mouth. It is also useful for the delivery of ionic drugs such as peptides.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of application Ser. No. 09/285,018 filed Apr. 1, 1999.[0001]
    • BACKGROUND OF THE INVENTION
  • This invention relates to a composition and a method for oral transmucosal delivery of active substances to a human or animal via the inner buccal cavity. More particularly, this invention relates to an improved dosage form which can easily adhere to the inner buccal cavity and sustain transmucosal release of drugs, odorants or any other ingredients and exhibit the activity effectively. [0002]
  • The sustained delivery of certain active substances, especially ionic peptide-based drugs, presents one of the greatest challenges in pharmaceutical science. Oral administration of pharmaceutical compositions has some drawbacks. For instance, it is difficult to keep the medicament at the desired location so that it can be absorbed, it is easily metabolized in the liver, and it is easily decomposed in the stomach. Accordingly, there has been much interest in the use of the mucosal lining of body cavities, for example the oral cavity, as the site of administration of active substances. Both the buccal and sublingual membranes offer advantages over other routes for administration. For example, drugs administered through the buccal and sublingual routes have a rapid onset of action, reach high levels in the blood, avoid the first-pass effect of hepatic metabolism, and avoid exposure of the drug to fluids of the gastrointestinal tract. Additional advantages include easy access to the membrane sites so that an active substance containing device can be applied, localized, and removed easily. Further, there is good potential for prolonged delivery through the mucosal membrane. M. Rathbone & J. Hadgraft, 74 [0003] Int'l J. of Pharmaceutics 9 (1991).
  • The sublingual mucosa includes the membrane of the ventral surface of the tongue and the floor of the mouth, whereas the buccal mucosa constitutes the lining of the cheek. The sublingual mucosa is relatively more permeable than the buccal mucosa, thus giving rapid absorption and acceptable bioavailability of many active substances. Furthermore, the sublingual mucosa is convenient, accessible, and generally well accepted. This route has been investigated clinically for the delivery of a substantial number of drugs. It is the preferred route for administration of nitroglycerin and is also used for buprenorphine and nifedipine. D. Harris & J. Robinson, 81 [0004] J. Pharmaceutical Sci. 1 (1992).
  • The buccal mucosa is less permeable than the sublingual mucosa. The rapid absorption and high bioavailabilities seen with sublingual administration of drugs is not generally provided to the same extent by the buccal mucosa. D. Harris & J. Robinson, 81 [0005] J. Pharmaceutical Sci. (1992) at 2. The permeability of the oral mucosa is probably related to the physical characteristics of the tissues. The sublingual mucosa is thinner than the buccal mucosa, thus permeability is greater for the sublingual tissue. The palatal mucosa is intermediate in thickness, but is keratinized thus lessening its permeability, whereas the other two tissues are not.
  • The ability of molecules to permeate through the oral mucosa appears to be related to molecular size, lipid solubility, ionization and many other factors. Small molecules, less than about 100 daltons, appear to cross the mucosa rapidly. As molecular size increases permeability decreases rapidly. Lipid-soluble compounds are more permeable through the mucosa than are non-lipid-soluble molecules. In this regard, the relative permeabilities of molecules seems to be related to their partition coefficients. The degree of ionization of molecules, which is dependent on the pK[0006] a of the molecule and the pH at the membrane surface, also greatly affects permeability of the molecules. Maximum absorption occurs when molecules are unionized or neutral in electrical charge and absorption decreases as the degree of ionization increases. Therefore, charged drugs, such as ionized polypeptide based drugs, present a significant challenge to absorption through the oral mucosa.
  • For a number of practical purposes it can be useful to affix a device containing an active substance within a mucosal-lined body cavity, such as the oral cavity. For example, conventional forms of substance delivery such as a lozenge, troche, breath freshener, mouth wash or spray work by shedding or admixing the substance into the saliva, which bathes the tissues of the oral cavity and throat as it passes posteriorly towards the esophagus. Such forms remain in the oral cavity only for short periods of time, generally not more than about 10 to 20 minutes, and they cannot always provide for effective sustained delivery of the substance. Moreover, the presence of a lozenge or troche in the user's mouth can be annoying or distracting, and may interfere with speech or with the ingestion of fluids. Holding the lozenge in the mouth to avoid either swallowing it or spitting it out requires conscious effort, and inadvertent loss can be embarrassing. [0007]
  • There are numerous instances where the active substance is intended for use at the site of delivery rather than absorption through mucosal membranes for systemic use. For example breath fresheners for the treatment of, or as a prophylactic against, halitosis, or agents for the treatment of xerostomia (dryness of the mouth) function directly in the oral cavity rather than through absorption. However, it would be desirable to have such agents held in place in the oral cavity to avoid the problems associated with lozenges or troches as noted above. [0008]
  • Various bioadhesives have been proposed for use in establishing adhesive contact with mucosal surfaces. See, for example, Biegajski, U.S. Pat. No. 5,700,478; Lowey, U.S. Pat. No. 4,259,314; Lowey, U.S. Pat. No. 4,680,323; Yukimatsu et al., U.S. Pat. No. 4,740,365; Kwiatek et al., U.S. Pat. No. 4,573,996; Suzuki et al., U.S. Pat. No. 4,292,299; Suzuki et al., U.S. Pat. No. 4,715,369; Mizobuchi et al., U.S. Pat. No. 4,876,092; Fankhauser et al., U.S. Pat. No. 4,855,142; Nagai et al., U.S. Pat. No. 4,250,163; Nagai et al., U.S. Pat. No. 4,226,848; Browning, U.S. Pat. No. 4,948,580; Schiraldi et al., U.S. Reissue Pat. No. Re. 33,093; and J. Robinson, 18 [0009] Proc. Intern. Symp. Control. Rel. Bioact. Mater. 75 (1991). Typically, these adhesives consist of a matrix of a hydrophilic, e.g., water soluble or swellable, polymer or mixture of polymers which can adhere to wet mucosal surfaces. Such polymers are inclusive of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxy ethylcellulose, ethylcellulose, carboxymethyl cellulose, dextran, gaur-gum, polyvinyl pyrrolidone, pectins, starches, gelatin, casein, acrylic acid, acrylic acid esters, acrylic acid copolymers, vinyl polymers, vinyl copolymers, vinyl alcohols, alkoxy polymers, polyethylene oxide polymers, polyethers, and the like. These adhesives may be formulated as ointments, thin films, tablets, troches, and other forms. Often, these adhesives have had medicaments mixed therewith to effectuate slow release or local delivery of a drug.
  • However, these known bioadhesives have several drawbacks. For example, adhesives in the form of pastes, creams or ointments are messy and inconvenient to use, and generally adhere poorly or not at all and are not suitable for extended periods of use. Some forms of adhesives, such as Carbopol (carboxyvinyl polymers), are not water soluble thus leave a tacky, greasy residue in the oral cavity of the wearer, and can cause sustained oral irritation. In addition, Carbopol based adhesives are ionic polymers which interact with ionic active substances, such as ionic polypeptide based drugs, and can inhibit absorption of such active substances. On the other hand, some forms of adhesives remain in the oral cavity for only short periods of time, e.g. generally not more than about 10 or 20 minutes, and therefore cannot provide for delivery of a substanceover an extended period of time. [0010]
  • Improved adhesives have been attained by using sodium alginate to overcome some of the problems associated with Carbopol based adhesives. However, sodium alginate is also an anionic polymer that shows ionic interaction with cationic active substances. Therefore, to formulate an adhesive having little or no interaction with ionic active substances, such as ionic polypeptide based drugs, would be highly desirable. [0011]
  • It has been discovered that polyvinyl pyrrolidone (PVP), without the presence of a plasticizer, used alone or in combination with other polymers or copolymers, has sufficient adhesion properties to the oral mucosa and also to polyacrylic denture materials to function surprisingly well to adhere devices containing active substances to the oral cavity. Since PVP is a non-ionic compound, a PVP-based mocoadhesive does not interact with ionic active substances. Moreover, PVP-based adhesives show a significant reduction in irritation of mucosa in human trials, compared to Carbopol-based adhesives. Although plasticized PVP has been used as an ingredient of bioadhesive compositions in prior art, a non-plasticized PVP based mucoadhesive has not heretofore been taught or suggested. In addition, the non-plasticized PVP based mucoadhesives of this invention show an improved stability when compared with prior mucoadhesives. [0012]
  • U.S. Pat. No. 4,740,365 discloses a sustained-release mucoadhesive preparation that may consist of one or two layers. However, the mucoadhesive layer is always a combination of two polymers components with a ratio of 95:5 to 5:95. One polymer component comprises one or more polymers selected from polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycol, alginic acid or a salt thereof, and an alternating copolymer of maleic anhydride and methyl vinyl ether. The other polymer component comprises one or more polymers selected from polyacrylic acid or a salt thereof. One aspect of the invention is to combine the two polymer components to maximize adhesive properties. U.S. Pat. No. 5,700,478 discloses a water-soluble pressure-sensitive adhesive including a water-soluble polymer that is made tacky at room temperature by addition of a water-soluble plasticizer that is miscible with the polymer. The presence of the plasticizer negatively affects the palatability and stability of the mucoadhesive. In addition to undesirable interaction with the ionic active substances, the presence of plasticizers or other ionic polymers in the mucoadhesive may also cause undesirable wearing properties or irritation. [0013]
  • Therefore, there is a need for a mucoadhesive that does not interact with ionic active substances and does not affect the palatability of the adhesive. The non-plasticized PVP-based mucoadhesive of the present invention also simplifies and reduces the cost of manufacture. In addition, a non-plasticized PVP-based mucoadhesive of this invention also reduces the unpleasant flavor and oral irritation associated with plasticizers or other copolymers. [0014]
    • OBJECTS AND SUMMARY OF THE INVENTION
  • It is an object of the present invention to provide a transmucosal delivery device which can adhere to the inner buccal cavity or palate for the delivery of active substances. [0015]
  • It is another object of the present invention to provide a transmucosal device for the delivery of active substances utilizing a mucoadhesive that is fully soluble in the secretions present in buccal cavity without having an objectionable taste or causing irritation. [0016]
  • It is also an object of the invention to provide a transmucosal device for the delivery of active substance utilizing a nonionic mucoadhesive thereby providing methods for administering both charged and uncharged active substances to humans and animals that allows easy accessibility to the site of administration. [0017]
  • It is a further object of the invention to provide dosage forms and methods for administering charged and uncharged active substances to humans and animals that allows for localization of the dosage form in the oral cavity over a sustained period to maximize active substance effects utilizing a mucoadhesive that dissolves in secretions present in the body cavities without having an objectionable taste or causing irritation. [0018]
  • It is still another object of the present invention to provide a transmucosal device for the delivery of active substances in a dosage form utilizing a nonionic mucoadhesive that provides for a method for administering charged and uncharged active substances to humans and animals wherein the device has acceptable tissue compatibility. [0019]
  • It is yet another object of the invention to provide a transmucosal device for the delivery of active substances utilizing a nonionic and nonplasticized mucoadhesive thereby providing a method for administering charged and uncharged active substances to humans and animals through the buccal and sublingual mucosa that avoids the objectionable taste or irritation associated with plasticized or ionic mucoadhesives. [0020]
  • These and other objects may be accomplished by a laminated active substances delivery device comprising a layer of mucoadhesive composition consisting primarily of PVP without a plasticizer. The non-plasticized PVP mucoadhesives of this invention can adhere to the inner buccal cavity or palate for delivering both charged and non-charged active substances. Such non-plasticized PVP mucoadhesives provide for localization of the active substance-containing delivery device over a sustained period to maximize drug effect and then dissolve in the secretions present in the buccal cavities without having an objectionable taste or causing irritation. The non-plasticized PVP mucoadhesive has sufficient adhesion not only to mucosal membranes but also to a variety of materials, such as polyacrylic denture material. [0021]
  • This invention therefore provides dosage forms having an adhesive surface suitable for affixing to the mucosal surface of the inner buccal cavity. In some dosage forms, the non-plasticized PVP mucoadhesive serves as a reservoir for the substances to be delivered, and releases the substances into the oral cavity as the adhesive dissolves. The active substance absorption also occurs via diffusion of the active substance through the adhesive layer of the device into the mucosal membrane. In some configurations a laminated device includes at least one active polymer layer in addition to the base mucoadhesive layer. Each layer may release one or more substances according to a desired timed delivery regime, for example, delayed onset delivery, pulsed delivery, and sequential delivery. The invention is particularly useful to deliver ionic active substance because the non-plasticized PVP mucoadhesives do not interact with ionic active substances and to the delivery of active substances intended for use directly in the oral cavity such as breath fresheners and saliva enhancing agents. The invention is uniquely suited to the delivery of breath freshening agents to the oral cavity particularly when the mucoadhesive layer is adhered to the hard palate or roof of the mouth. [0022]
    • DETAILED DESCRIPTION OF THE INVENTION
  • For the purposes of this disclosure the following definitions will apply: [0023]
  • “Active substance,” “drugs” or “agents” refers to all functional compounds which are desirable to be delivered via oral cavity, either charged or non-charged, including but not limited to, medicaments for oral diseases, diseases of the teeth and also systemic diseases, oral odorants such as breath freshening agents, saliva stimulants, nutritional supplements such as vitamins, herb extracts or minerals, and mixtures thereof. For example, odorants suitable for masking or refreshing objectionable breath including peppermint, spearmint, menthol, grape, cherry, lemon, strawberry, orange, licorice, lime and any mixtures thereof. Active substances to be delivered by the device of the present invention includes ionic or non-ionic drugs for oral or systemic diseases, for example, peptide drugs (e.g. calcitonin, DDAVP), analgesics and antiinflammatory agents (e.g. indomethacin, ibuproden), mouth disinfectants (chlorohexidine hydrochloride, hexylresorcine), cardiovascular agents (e.g. nitroglycerin, isosorbide dinitrate, nifedipine), antiasthmatics (e.g. disodium cromoglycate), antibiotics (e.g. penicillin, erythromycin), chemotherapeutics (e.g. sulfathiazole, nitrofurazone), local anesthetics (e.g. benzocaine), cardiotonics (e.g. digitalis, digoxin), antitussives and expectorants (e.g. codeine phosphate, isoproterenol hydrochloride), agents affecting digestive organs, antihistamines, anti-inflammatory steroids, hemostatics, sexual hormones, sedatives, antitumor agents, or the like. [0024]
  • “Mucoadhesive,” refers to hydrophilic polymers, natural or synthetic, which, by the hydrophilic designation, can be either water soluble or swellable and which are adhesive to mucosal surfaces. Preferably such adhesives adhere the active substances-containing formulation to the mucosal tissues as well as functioning as a reservoir of active substances which can be dissolved or absorbed via contacting the mucosal membrane. [0025]
  • “PVP”, “polyvinylpyrrolidone”, “PVP mucoadhesive”, “non-plasticized PVP mucoadhesive” and the like refers to a mucoadhesive composition consisting essentially of PVP polymer that does not contain any plasticizers. Polyvinylpyrrolidone is a homopolymer of 1-ethenyl-2pyrrolidinone and is available in various grades under the generic or tradename “Povidone”. Mixtures of one or more grades or molecular weights of PVP polymers may be utilized. Preferably PVP polymers will have an average molecular weight of between about 10,000 and 700,000. Other functionally suitable hydrophilic ionic or nonionic polymers or copolymers conventionally used in adhesive formulations may be combined with the nonplasticized PVP depending on use. If the substance to be delivered is nonionic it may not be disadvantageous to utilize some ionic polymers or copolymers. On the other hand, when delivering an ionic substance, it is preferred that an added hydrophilic polymer be nonionic. [0026]
  • Typical of hydrophilic polymers or copolymers that may be combined with PVP include acrylic acid polymers, e.g. carboxyvinyl or carboxymethylene polymers such as sold under the generic of tradenames “Carbomer” and “Carbopol”; hydroxypropyl cellulose such as sold under the tradename “Klucel”; methylcellulose such as sold under the tradename “Methocel” and polyethylene oxide polymers such as sold under the tradename “Polyox”. [0027]
  • “Permeation enhancer,” “enhancer,” “penetration enhancer,” or similar term means a material that achieves such permeation enhancement, and an “effective amount” of an enhancer means an amount effective to enhance penetration through the mucosa of a selected agent to a selected degree. Taurocholic acid and its salts are exemplary of transmucosal enhancers. [0028]
  • This invention features a laminated active substance delivery system which includes at least one active substance containing polymer layer in addition to a mucoadhesive polymer layer which may also contain active substances. The system releases one or more substances according to a desired time delivery regime. For example, onset of release may be delayed following placement of the delivery system within the body cavity, or a substance may be released at different rates over time, or in pulses with intervening periods in which essentially no release occurs. Alternatively, two or more substances may be sequentially released, with or without an intervening period in which no substance is released. The pattern of release is established by the sequential arrangement of laminates containing the substances, and the concentration of the substances contained in the various layers. [0029]
  • The mucoadhesive composition of this invention consists primarily of nonplasticized PVP. The mucoadhesive can be 100% PVP. However, when an additional polymer or copolymer is used in the mucoadhesive composition, the ratio of PVP to such other polymers or copolymers will be at least 1:1 and will be preferably between 1:1 and 20:1. In other words, nonplasticized PVP will make up between about 50 to 95% by weight of the mucoadhesive composition with the remaining 5 to 50% by weight being a functionally suitable polymer or copolymer. [0030]
  • The mucoadhesive composition will make up between about 20-99% by weight of the adhesive layer the with remaining 1 to 80% by weight being a member selected from the group consisting of water soluble compounding agents and any active substances added to the adhesive layer. By “compounding agents” is meant inert ingredients or formulation aids such as lactose, mannitol, magnesium stearate, flavoring agents, coloring agents, stabilizers, binding agents, or any other fillers which do not have a negative impact on the function of the mucoadhesive layer. The non-plasticized PVP mucoadhesives are fully water-soluble, and are thus fully soluble in secretions present in oral mucosa without having an objectionable taste or causing sustained irritation. In addition, the non-plasticized PVP mucoadhesives are nonionized and thus are particularly useful to affix a transmucosal delivery formulation for ionic active substances such as polypeptide drugs. [0031]
  • The mucoadhesives of this invention can be used to affix any oral delivery device within the oral cavity, e.g. patches, tablets, and the like. It is particularly useful in construction of a laminated or multi-layered device for controlled delivery of substances within the oral cavity. The non-plasticized PVP mucoadhesive layer can serve as a reservoir for the active substances to be delivered, and releases the substance into the oral cavity as the adhesive dissolves. The substances can also be transmucosally absorbed through the adhesive layer which is in contact with an oral mucosal membrane. [0032]
  • While laminated or multilayered devices will be described with more particularity below, the release rate of an active substance from a particular layer is determined basically by the rate at which the layer dissolves or disperses in the fluid milieu of the oral cavity, and by the diffusion rate of the active substance from particular layer which is dependent upon the concentration of the active substances within the layer. Release from a more basally situated layer may be delayed by an overlaying layer(s), and the duration of the delay in delivery from such a particular layer is determined basically by the time required for the overlaying layer(s) to disperse. The active substances contained in the adhesive layer can also be absorbed via the contacting mucosal membrane and the absorption may be enhanced by addition of a suitable penetration enhancer into the formulation of either the adhesive layer or an active or overlying layer or both. The concentration of the active substance will be an “effective amount,” which is the amount required to achieve the desired delivery either into the oral cavity and/or across mucosal tissues at a rate and for a time which will achieve the desired physiological effect. Those concentrations can be readily determined by the practitioner based upon the active substance selected. [0033]
  • As an indication of the variances in active substance concentration in the mucoadhesive layer which may provide “effective amounts,” it is readily apparent that the active substance concentration will, of necessity, be determined by the active substance being utilized and its potency and/or bioavailability. For example, when the active substance is a drug an effective amount will be much smaller than when the active substance is a breath freshener. Effective amounts of an active drug substance may be as little as 0.1% and may be as much as 10% of the mucoadhesive layer. Preferably amounts will be between about 0.2 and 5.0% by weight. On the other hand, effective amounts of breath fresheners vary from about 10 to 60% by weight of the mucoadhesive layer with amounts of between about 20 and 50% being preferred. [0034]
  • As previously stated, the pressure-sensitive mucoadhesive composition of the mucoadhesive layer consists essentially of nonplasticized PVP or a combination of PVP and suitable polymers or copolymers. The concentration of mucoadhesive in the layer will be between about 20 and 99% by weight. Preferably the mucoadhesive concentration is between about 30 and 80%. The remaining amounts are made up from one or more members selected from the group consisting of water soluble compounding agents and any active substances. Such compositions show sufficient adhesion to oral mucosal surfaces of animals such dogs and also to humans and to denture materials. The non-plasticized PVP mucoadhesives of this invention are water soluble, and are capable of conforming to and adhering to contoured surfaces such as the gums, the roof of the mouth and buccal lining of the mouth. Such mucoadhesives can be used as part of a system for delivery of substances through the oral mucosa (as a buccal transmucosal patch), for delivery of substances into the oral cavity itself, or the combination of both via a laminated configuration, which may be either in the form of a tablet or patch. Both patches and tablets are prepared such that the mucoadhesive layer contains the non-plasticized PVP adhesive which may or may not contain a drug/enhancer, while the other layer(s) is non-adhesive, at least on the outer surface, and contains one or more drugs/enhancer combinations, breath fresheners or other active substances. [0035]
  • One preferred embodiment of this invention features a layered composite for delivery of an active substance into the oral cavity, having an outer active layer that includes the active substances dispersed or dissolved in a water soluble polymer, and the above-described water soluble mucoadhesive layer. Also as noted above, the rate of release of the active substance within the oral cavity depends partially on the rate of dissolution or dispersion of the polymer of the active layer. As previously mentioned, active substances may also be included in the adhesive layer which may be released with the dissolution of the adhesive layer, and be absorbed by the contacting mucosal membrane as well. [0036]
  • The active or outer layer of a bilayer or multilayer system is laminated to the mucoadhesive layer by conventional techniques. The active layer is also based on the presence of a water soluble polymer in which is dispersed the active substance to be delivered along with other compounding agents such as referenced above. Preferably the water soluble polymer will be present in amounts of between about 3 and 60% by weight of such hydrophilic polymers or copolymers. Typical of hydrophilic polymers or copolymers that may be used in the active layer include those mentioned above for use in the mucoadhesive layer such as acrylic acid polymers, hydroxypropyl cellulose, methylcellulose, polyethylene oxide and polyvinyl pyrrolidone, as well as natural polymers such as gaur-gum, pectins, starches, gelatin, casein and the like. These water soluble polymers are compatible with the active substances to be delivered. Preferably such polymers are selected to promote desired active substance release profiles and do not adversely affect the activity of such substance. [0037]
  • The active or overlying layer(s) will contain an “effective amount” of the active substance being delivered. As in the mucoadhesive layer, the effective amount of active substance will be determined by the active substance being utilized and its potency and/or bioavailability. Those amounts may be the same as in the mucoadhesive layer but may be higher when the mucoadhesive layer is utilized primarily to secure a device to the oral mucosa. For example, when the active substance is a drug an effective amount will be much smaller than when the active substance is a breath freshener. Effective amounts of an active drug substance may be as little as 0.1% and may be as much as 10% of the mucoadhesive layer. Preferably amounts will be between about 0.2 and 5.0% by weight. On the other hand, effective amounts of breath fresheners vary from about 1 to 60% by weight of the mucoadhesive layer with amounts of between about 5 and 40% being preferred. [0038]
  • The active layer may also contain from between about 40 and 99.9% by weight of compounding agents as defined above. [0039]
  • The active substance delivery system of this invention is particularly useful for administering a substance over an extended time period for relief of oral symptoms such as bad breath, sore throat, cough, dry mouth or other similar symptoms. [0040]
  • For example, odorants suitable for masking or refreshing objectionable breath include agents such as mint, spearmint, menthol, grape, cherry, lemon, strawberry, orange, licorice, peppermint, lime and any mixtures thereof. Other substances which are suitable for being transmucosally administered by the delivery system of this invention include but are not limited to saliva stimulants, nutritional supplements such as vitamins, herb extracts or minerals, and mixtures thereof. [0041]
  • The device of the present invention is also suitable for transmucosally delivery of both ionic or non-ionic drugs for oral or systemic diseases including analgesics and anti-inflammatory agents (e.g. indomethacin, ibuproden), mouth disinfectants (chlorohexidine hydrochloride, hexylresorcine), enzymes (e.g. nitroglycerin, isosorbide dinitrate, nifedipine), antiasthmatics (e.g. disodium cromoglycate), antibiotics (e.g. penicillin, erythromycin), chemotherapeutics (e.g. sulfathiazole, nitrofurazone), local anesthetics (e.g. benzocaine), cardiotonics (e.g. digitalis, digoxin), antitussives and expectorants (e.g. codeine phosphate, isoproterenol hydrochloride), agents affecting digestive organs, antihistamines, antiinflammatory steroids, hemostatics, sex hormones, sedatives, antitumor agents, or the like. Effective amounts, i.e. from 2 to 20% by weight, of penetration enhancers such as a salt of a conjugate of a bile acid with taurine or taurocholic acid may be optionally added in the active layer to enhance the penetration of the active drug. [0042]
  • The most preferred embodiment of this invention features a laminated device for administering an active agent into the oral cavity over an extended period of time and having the device dissolve without leaving an objectionable taste or cause-sustained irritation to the oral cavity. The device can be either a laminated film or tablet, having at least two layers, including a basal layer of a pressure-sensitive, water-soluble, non-plasticized PVP mucoadhesive composition, which may or may not contain an active agent, and an active agent containing water soluble polymer layer. The device is affixed to the mucosal surface, preferably the palatine surface of the oral cavity via the mucoadhesive layer of the device. [0043]
  • As previously stated, the systems utilized in the present invention comprise an active layer containing the active substances and a basal mucoadhesive layer which may also contain an active substance. The systems may be in either the form of a tablet or a patch. Bilayer tablets are made by classical bilayer tablet compression techniques on a suitable press. Layers of a bilayer tablets consisting of an active non-adhesive layer and an adhesive layer may contain layers which are of different colors to distinguish the layers for purposes of application. The identification of the active non-adhesive layer facilitates application by the patient and prevents incidental adhesion of other oral tissues to the tablet. The active layer is prepared by dry mixing the ingredients and compressing them into a tablet or by wet granulating the ingredient mixture and then compressing according to accepted pharmaceutical techniques. In general, it has been found suitable to mix the active substances, polymer and any formulation aids such as magnesium stearate, lactose, flavors, and the like and then compress the mix in a press at about 0.2-0.5 tons for a dwell time of 2-10 seconds. [0044]
  • The adhesive layer is first prepared by intimately admixing PVP, copolymers, and tableting excipients and binding compounds such as sorbitol, dyes, flavors, magnesium stearate, mannitol and the like. This may be formulated as a dry mix or accomplished by conventional wet granulation and screening techniques followed by drying. In either event, the blended adhesive layer ingredients are then placed on top of the partially compressed active layer and both layers are then compressed at a higher pressure, for example from 0.5 to 1.5 tons for an additional 2-10 seconds dwell time. [0045]
  • In some embodiments the active substance is an odorant such as an essential oil of a plant material, a refined fraction of an essential oil, or a combination of the chief aromatic constituents of an essential oil. Preferably, the odorant is a mint such as obtained from oils of peppermint, spearmint or wintergreen. Any other suitable odorant or masking agent may also be used such as menthol, grape, cherry, lemon, strawberry, orange, licorice, lime and any mixtures thereof. In other embodiments the active substances may be saliva stimulants, or nutritional supplements such as vitamins, herb extracts or minerals, and mixtures thereof. [0046]
  • The systems of the present invention will preferably be sized to provide a device having a contact surface area of between about 0.5 to 10 cm[0047] 2 for adhering the the adhesive layer and the mucosal surface. Areas of between about 0.5 to 5 cm2 are preferred with areas of between about 1.0 and 5 cm2 being optimal. The active mucoadhesive layers will generally have a thickness of between about 0.1 and 3 mm with thicknesses of between about 0.5 and 2 mm being preferred.
  • Extended delivery of active substances can be obtained according to the bilayered or multilayered device according to the present invention. The rate of release of the active substances within the oral cavity can be specified by selection of particular polymer or polymer combinations. The device according to the present invention is capable of adhering to contoured surfaces such as the gum or the roof of the mouth. The device can deliver the active substances over a period of up to 2 hours or longer from a single device, and can dissolve without leaving any bad taste or causing sustained irritation. The device according to this invention is particularly useful in delivering charged drugs such as polypeptide based drugs because the PVP mucoadhesive is non-ionic which does not interact with ionic drugs to be delivered. Further, the device is particularly adaptable for the delivery of odorants or other active agents for the treatment of halitosis or dryness of the mouth.[0048]
  • The following examples are illustrative of methods of preparing both bilayer tablets. [0049]
    • EXAMPLE 1
  • With the proviso that the mucoadhesive layer must contain the above designated percent by weight of a PVP or a PVP and copolymer combination, bilayered breath freshener tablets are prepared in the following manner containing the designated ingredients within the ranges specified. An active layer is prepared by transferring the specified amounts of the following ingredients into a V blender [0050]
    Weight Percentage
    Ingredients Range (%)
    Mint Powder 1-80
    co-polymer 5-70
    Sweetener 0.1-20  
    Magnesium Stearate 0.1-10  
    Mannitol 0-80
    Dye 0.1-0.8 
  • and blended for a specified amount of time. In certain instances, where liquid flavorings are utilized, it is necessary to mix the blended material in a suitable low shear mixer along with the flavoring agent. The blended material is then discharged into a suitable container. The active layer blend is then passed through the Fitzmill using the specified screen. Dye and magnesium stearate are added and blended for a specified amount of time. [0051]
  • An adhesive layer is prepared by transferring the specified amounts of the following ingredients into a V blender: [0052]
    Weight Percentage
    Ingredients Range(%)
    Mint Powder 1-80
    PVP 20-90 
    Carbopol  0-4.8
    co-polymer 0-80
    Sweetener 0.1-20  
    Mannitol 0-80
  • and blended for a specified amount of time. The blended materials are then discharged into a suitable container. The adhesive layer blend is then passed through the Fitzmill using the specified screen. The specific amount of magnesium stearate is calculated based on the yield of the adhesive layer blend (0.5-10% by weight), and then added to the blender and blended for a specified amount of time. The final blended materials are collected into tared polyethylene lined containers. [0053]
  • The tablet press was set up for bi-layered operation using the specified parameters. The final blended powder for the active layer granulation was placed in the first hopper and the adhesive granulation was placed into the second hopper. The tablet press was set to a specified amount of active layer prior to introducing the specified amount of the adhesive granulation. The compressed tablets were packaged into bottles and labeled with the proper information. [0054]
  • The following are exemplary of other oral transmucosal (OTM) tablet formulations which are within the scope of this invention. However, they are illustrative only and are not intended to define the scope of the invention. These tablets can be conveniently formulated according to the method described in Example 1. [0055]
    • EXAMPLE 2
  • This example illustrates a bilayer oral transmucosal tablet for rapid onset delivery of drugs formulated according to the method described in Example 1. The drug to be delivered in this example is Buprenorphine HCL and the penetration enhancer is taurocholic cid. The adhesive layer contains 60% non-plasticized PVP. [0056]
  • Buprenorphine HCL Rapid Onset [0057]
    Active Layer % w/w Adhesive Layer % w/w
    Buprenorphine HCL 0.86 Mannitol 39.25
    Mannitol 70.66  Povidone K90 40.00
    Taurocholic Acid 4.00 Povidone K30 20.00
    Klucel HXF 10.00  Magnesium Stearate  0.75
    Povidone K30 5.00
    Sod. Bicarbonate 8.57
    Sod. Carbonate 0.06
    FD&C Yellow #6 0.10
    Magnesium Stearate 0.75
    • EXAMPLE 3
  • This example illustrate a bilayer oral transmucosal tablet for long acting delivery of drugs formulated according to the method described in Example 1. The active substance in this example is Buprenorphine HCL, the penetration enhancer is taurocholic acid. The adhesive layer contains 60% non-plasticized PVP and 10% of an acrylic copolymer. [0058]
  • Buprenorphine HCL Long Acting [0059]
    Active Layer % w/w Adhesive Layer % w/w
    Buprenorphine HCL 1.86 Mannitol 29.25
    Mannitol 37.16  Povidone K90 40.00
    Taurocholic Acid 12.00  Carbomer 934 P 10.00
    Klucel HXF 30.00  Povidone K30 20.00
    Carbomer 934P 4.50 Magnesium Stearate  0.75
    Povidone K30 5.00
    Na Bicarbonate 8.57
    Na Carbonate 0.06
    FD&C Yellow #6 0.10
    Mg Stearate 0.75
    • EXAMPLE 4
  • This example illustrate a bilayer oral transmucosal tablet for rapid onset delivery of drugs formulated according to the method described in Example 1. The active substance in this example is Fentanyl Citrate, the penetration enhancer is taurocholic acid. The adhesive layer contains 70% non-plasticized PVP. [0060]
  • Fentanyl Citrate [0061]
    Active Layer % w/w Adhesive Layer % w/w
    Fentanyl Citrate 0.63 Mannitol 29.25
    Mannitol 74.89  Povidone K90 40.00
    Taurocholic Acid 10.00  Povidone K30 30.00
    Klucel HXF 5.00 Magnesium Stearate  0.75
    Sodium Bicarbonate 1.06
    Sodium Carbonate 7.57
    FD&C Yellow #6 0.10
    Magnesium Stearate 0.75
    • EXAMPLE 5
  • This example illustrate a bilayer oral transmucosal tablet for long acting delivery of drugs formulated according to the method described in Example 1. The active substance in this example is Fentanyl Citrate, the penetration enhancer is taurocholic acid. The adhesive layer contains about 70% non-plasticized PVP and 20% copolymer. [0062]
  • Fentanyl Citrate Long Acting [0063]
    Active Layer % w/w Adhesive Layer % w/w
    Fentanyl Citrate 0.63 Povidone K90 40.00
    Mannitol 70.89  Carbomer 934P 20.00
    Taurocholic Acid 10.00  Povidone K30 39.25
    Carbomer 934P 4.00 Magnesium Stearate  0.75
    Klucel HXF 5.00
    Sod. Bicarbonate 7.57
    Sod. Carbonate 1.06
    FD&C Yellow #6 0.10
    Magnesium Stearate 0.75
    • EXAMPLE 6
  • This example illustrate a bilayer oral transmucosal tablet for delivery of drugs formulated according to the method described in Example 1. The active substance in this example is DDAVP, the penetration enhancer is taurocholic acid. The adhesive layer contains about 70% non-plasticized PVP and 5% of an acrylic copolymer. [0064]
  • OTM Tablet for DDAVP [0065]
    Active Layer % w/w Adhesive Layer % w/w
    DDAVP  2.23 Mannitol 24.25
    Mannitol 42.92 Povidone K90 40.00
    Taurocholic Acid 15.00 Carbomer 934P  5.00
    Magnasweet 100 15.00 Povidone K30 30.00
    Klucel HXF 24.00 Magnesium Stearate  0.75
    FD&C Yellow #6  0.10
    Magnesium Stearate  0.75
    • EXAMPLE 7
  • This example illustrate a bilayer oral transmucosal tablet for delivery of drugs formulated according to the method described in Example 1. The active substance in this example is calcitonin, the penetration enhancer is taurocholic acid. The adhesive layer contains about 30% non-plasticized PVP and 20% of an acrylic copolymer. [0066]
  • OTM Tablet for Calcitonin [0067]
    Active Layer % w/w Adhesive Layer % w/w
    Calcitonin 3.01 Mannitol 49.25
    Mannitiol 60.29  Povidone K90 20.00
    Taurocholic Acid 5.00 Carbomer 934P 20.00
    Acelsulfame K 1.00 Povidone K30 10.00
    Klucel HXF 30.00  Magnesium Stearate  0.75
    FD&C Yellow #6 0.20
    Magnesium Stearate 0.50
    • EXAMPLE 8
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening formulated according to the method described in Example 1. The active substance in this example is menthol mint (50% by weight in active the layer and 30% by weight in the adhesive layer). The adhesive layer contains about 35% non-plasticized PVP. [0068]
  • OTM Tablet of Menthol Mint for Breath Refreshening [0069]
    Active Layer % w/w Adhesive Layer % w/w
    Menthol Mint 50.00 Menthol Mint 30.00
    Mannitol 38.30 Mannitol 34.25
    Acelsulfame K  1.00 Povidone K90 25.00
    Povidone K30 10.00 Povidone K30 10.00
    FD&C Yellow #6  0.20 Magnesium Stearate  0.75
    Magnesium Stearate  0.50
    • EXAMPLE 9
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening formulated according to the method described in Example 1. The active substance in this example is licorice (20% by weight in the active layer and 30% by weight in the adhesive layer). The adhesive layer contains about 50% non-plasticized PVP. [0070]
  • OTM Tablet of Licorice for Breath Refreshening [0071]
    Active Layer % w/w Adhesive Layer % w/w
    Licorice 20.00 Licorice 30.00
    Mannitol 44.30 Mannitol 19.25
    Magnasweet 100  5.00 Povidone K90 30.00
    Xylitol 30.00 Povidone K30 20.00
    FD&C Yellow #6  0.20 Magnesium Stearate  0.75
    • EXAMPLE 10
  • This example illustrate a bilayer oral transmucosal tablet for long acting breath refreshening formulated according to the method described in Example 1. The active substance in this example is menthol mint (40% by weight in the active layer and 30% by weight in the adhesive layer). The adhesive layer contains about 40% non-plasticized PVP and 15% copolymer. [0072]
  • OTM Tablet of Menthol Mint Long Acting [0073]
    Active Layer % w/w Adhesive Layer % w/w
    Menthol Mint 40.00 Menthol Mint 30.00
    Mannitol 49.30 Mannitol 14.25
    Acelsulfame K 1.00 Povidone K90 30.00
    Carbomer 934P 4.00 Povidone K30 10.00
    Methocel 5.00 Carbomer 934P 15.00
    FD&C Yellow #6 0.20 Magnesium Stearate 0.75
    Magnesium Stearate 0.50
    • EXAMPLE 11
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening and dry mouth relief formulated according to the method described in Example 1. The active substances in this example are eucalyptus oil in the active layer and spearmint in the adhesive layer. The adhesive layer contains a polymer combination of about 20% non-plasticized PVP and 15% copolymer. [0074]
  • OTM Tablet of Eucalyptus and Spearmint [0075]
    Active Layer % w/w Adhesive Layer % w/w
    Eucalyptus Oil 0.75 Spearmint 30.00
    Mannitol 47.55 Mannitol 34.25
    Acelsulfame K 1.00 Povidone K90 10.00
    Klucel HXF 50.00 Carbomer 934P 15.00
    FD&C Yellow #6 0.20 Povidone K30 10.00
    Magnesium Stearate 0.50 Magnesium Stearate 0.75
    • EXAMPLE 12
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening and dry mouth relief formulated according to the method described in Example 1. The active substances in this example is peppermint (40% by weight in the active layer and 30% by weight in the adhesive layer). The adhesive layer contains about 35% non-plasticized PVP. [0076]
  • OTM Tablet of Peppermint for Breath Refreshening [0077]
    Active Layer % w/w Adhesive Layer % w/w
    Peppermint 40.00 Peppermint 30.00
    Lactose 53.30 Mannitol 9.25
    Acelsulfame K 1.00 Povidone K90 50.00
    Methocel 5.00 Povidone K30 10.00
    FD&C Yellow #6 0.20 Magnesium Stearate 0.75
    Stearic Acid 0.50
    • EXAMPLE 13
  • This example illustrate a bilayer oral transmucosal tablet for breath refreshening and dry mouth relief formulated according to the method described in Example 1. The active substances in this example is spearmint (30% by weight in the active layer and 30% by weight in the adhesive layer). The adhesive layer contains about 20% non-plasticized PVP and 15% copolymer. [0078]
  • OTM Tablet of Spearermint for Breath Refreshening [0079]
    Active Layer % w/w Adhesive Layer % w/w
    Spearmint 30.00 Spearmint 30.00
    Mannitol 38.30 Mannitol 34.25
    Acelsulfame K 1.00 Povidone K90 10.00
    Klucel HXF 30.00 Carbomer 934P 15.00
    FD&C Yellow #6 0.20 Povidone K30 10.00
    Stearic Acid 0.50 Stearic Acid 0.75
  • While the above examples illustrate numerous embodiments of the invention, the scope of which is limited only by the operability exhibited by improved mucosal adhesive properties attributable to the non-plasticized PVP. The invention is not limited to any specific active substance or groups of substances as these are known in the art. Rather, the invention is drawn to the use of a non-plasticized PVP as a mucoadhesive for a transmucosal delivery device which has improved mucosal adhesive properties, e.g. It does not have an objectionable taste or interact with an ionic active substances to be delivered. It is, therefore, limited in scope only by the appended claims and their functional equivalents. [0080]

Claims (47)

What is claimed is:
1. A device for the oral transmucosal delivery of active substances to the oral cavity comprising a mucoadhesive layer and at least one overlying active substance layer said mucoadhesive layer having one surface adapted to contact the mucosal surface of the oral cavity for adhering thereto and an opposing surface in contact with and adhering to an overlying active substance containing layer characterized in that the mucoadhesive layer contains a mucoadhesive composition comprising at least 50% by weight of a non-plasticized polyvinyl pyrrolidone polymer having a weight average molecular weight of between about 10,000 and 700,000.
2. A device according to
claim 1
 wherein said mucoadhesive layer contains from 20 to 99% by weight of said mucoadhesive composition.
3. A device according to
claim 2
 wherein said mucoadhesive composition consists of non-plasticized polyvinyl pyrrolidone polymer.
4. A device according to
claim 2
 wherein said mucoadhesive composition comprises about 50 to 95% by weight of non-plasticized polyvinyl pyrrolidone polymer and 5 to 50% by weight of an additional functionally suitable hydrophilic polymer or copolymer.
5. A device according to
claim 4
 wherein said additional hydrophilic polymer or copolymer is a member selected from the group consisting of acrylic acid polymers, hydroxypropyl cellulose, methylcellulose, polyethylene oxide, polyvinyl pyrrolidone, gaur-gum, pectins, starches, gelatin and casein.
6. A device according to
claim 3
 or
4
 wherein the overlying active substance layer contains from about 3 to 60% by weight of a hydrophilic polymer in which the active substance is intimately contained.
7. A device according to
claim 6
 wherein the active substance is a breath freshener and is present in the active substance layer in amounts of between about 10 to 60% by weight.
8. A device according to
claim 7
 wherein the mucoadhesive layer also contains an active substance in amounts of between about 5 to 40% by weight.
9. A device according to
claim 8
 wherein the mucoadhesive composition content of the mucoadhesive layer is present in amounts of between about 20 to 60% by weight.
10. A device according to
claim 9
 wherein the breath freshener is an odorant member selected from the group consisting of peppermint, spearmint, menthol, grape, cherry, lemon, strawberry, orange, licorice, lime and any mixtures thereof.
11. A device according to
claim 8
 wherein the surface area of said mucoadhesive layer adapted for contact with the mucosal surface is between about 0.5 and 10 cm2.
12. A device according to
claim 11
 wherein said device is a tablet.
13. A device according to
claim 12
 wherein the thickness of the mucoadhesive layer is between about 0.1 and 3 mm.
14. A device according to
claim 6
 wherein the active substance is a drug and is present in the active substance layer in amounts of between about 0.1 to 10% by weight.
15. A device according to
claim 14
 wherein the drug is an ionic drug.
16. A device according to
claim 15
 wherein said ionic drug is a peptide.
17. A device according to
claim 14
 wherein the mucoadhesive layer also contains a chemical permeation enhancer in amounts of between about 2 to 20% by weight.
18. A device according to
claim 17
 wherein the chemical permeation enhancer is a bile acid or a salt thereof.
19. A device according to
claim 18
 wherein said drug is an ionic drug.
20. A device according to
claim 19
 wherein said ionic drug is a peptide.
21. A device according to
claim 14
 wherein the surface area of said mucoadhesive layer adapted for contact with the mucosal surface is between about 0.5 and 10 cm2.
22. A device according to
claim 21
 wherein said device is a tablet.
23. A device according to
claim 22
 wherein the thickness of the mucoadhesive layer is between about 0.1 and 3 mm.
24. A method for the oral transmucosal delivery of active substances to the oral cavity comprising applying to the mucosa of said oral cavity a device comprising a mucoadhesive layer and at least one overlying active substance layer said mucoadhesive layer having one surface which is in contact with the mucosal surface of the oral cavity and adhering thereto and having an opposing surface in contact with and adhering to an overlying active substance containing layer characterized in that the mucoadhesive layer contains a mucoadhesive composition comprising at least 50% by weight of a non-plasticized polyvinyl pyrrolidone polymer having a weight average molecular weight of between about 10,000 and 700,000; retaining said device adhering to said mucosa until said active substance in said active substance layer has been released and said active substance layer and said mucoadhesive layer have dissolved in said oral cavity.
25. A method according to
claim 24
 wherein said mucoadhesive layer contains from 20 to 99% by weight of said mucoadhesive composition.
26. A method according to
claim 25
 wherein said mucoadhesive composition consists of non-plasticized polyvinyl pyrrolidone polymer.
27. A method according to
claim 25
 whrein said mucoadhesive composition comprises about 50 to 95% by weight of non-plasticized polyvinyl pyrrolidone polymer and 5 to 50% by weight of an additional functionally suitable hydrophilic polymer or copolymer.
28. A method according to
claim 27
 wherein said additional hydrophilic polymer or copolymer is a member selected from the group consisting of acrylic acid polymers, hydroxypropyl cellulose, methylcellulose, polyethylene oxide, polyvinyl pyrrolidone, gaur-gum, pectins, starches, gelatin and casein.
29. A method according to
claim 26
 or
27
 wherein the overlying active substance layer contains from about 3 to 60% by weight of a hydrophilic polymer in which the active substance is intimately contained.
30. A method according to
claim 29
 wherein the active substance is a breath freshener and is present in the active substance layer in amounts of between about 10 to 60% by weight.
31. A method according to
claim 30
 wherein the mucoadhesive layer also contains an active substance in amounts of between about 5 to 40% by weight.
32. A method according to
claim 31
 wherein the mucoadhesive composition content of the mucoadhesive layer is present in amounts of between about 20 to 60% by weight.
33. A method according to
claim 32
 wherein the device is adhered to the hard palate.
34. A method according to
claim 33
 wherein the breath freshener is an odorant member selected from the group consisting of peppermint, spearmint, menthol, grape, cherry, lemon, strawberry, orange, licorice, lime and any mixtures thereof.
35. A method according to
claim 33
 wherein the surface area of said mucoadhesive layer adapted for contact with the mucosal surface is between about 0.5 and 10 cm2.
36. A method according to
claim 35
 wherein said device is a tablet.
37. A method according to
claim 36
 wherein the thickness of the mucoadhesive layer is between about 0.1 and 3 mm.
38. A method according to
claim 30
 wherein the active substance is a drug and is present in the active substance layer in amounts of between about 0.1 to 10% by weight.
39. A method according to
claim 38
 wherein the drug is an ionic drug.
40. A method according to
claim 39
 wherein said ionic drug is a peptide.
41. A method according to
claim 38
 wherein the mucoadhesive layer also contains a chemical permeation enhancer in amounts of between about 2 to 20% by weight.
42. A method according to
claim 41
 wherein the chemical permeation enhancer is a bile acid or a salt thereof.
43. A method according to
claim 42
 wherein said drug is an ionic drug.
44. A method according to
claim 43
 wherein said ionic drug is a peptide.
45. A method according to
claim 38
 wherein the surface area of said mucoadhesive layer adapted for contact with the mucosal surface is between about 0.5 and 10 cm2.
46. A method according to
claim 45
 wherein said device is a tablet.
47. A method according to
claim 46
 wherein the thickness of the mucoadhesive layer is between about 0.1 and 3 mm.
US09/774,271 1999-04-01 2001-01-30 Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity Abandoned US20010051186A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/774,271 US20010051186A1 (en) 1999-04-01 2001-01-30 Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/285,018 US6210699B1 (en) 1999-04-01 1999-04-01 Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US09/774,271 US20010051186A1 (en) 1999-04-01 2001-01-30 Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/285,018 Continuation US6210699B1 (en) 1999-04-01 1999-04-01 Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity

Publications (1)

Publication Number Publication Date
US20010051186A1 true US20010051186A1 (en) 2001-12-13

Family

ID=23092391

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/285,018 Expired - Lifetime US6210699B1 (en) 1999-04-01 1999-04-01 Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US09/774,271 Abandoned US20010051186A1 (en) 1999-04-01 2001-01-30 Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/285,018 Expired - Lifetime US6210699B1 (en) 1999-04-01 1999-04-01 Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity

Country Status (5)

Country Link
US (2) US6210699B1 (en)
EP (1) EP1089686A1 (en)
AU (1) AU764912B2 (en)
CA (1) CA2333156A1 (en)
WO (1) WO2000059423A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226925A1 (en) * 2004-02-17 2005-10-13 Transoral Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
JP2006502972A (en) * 2002-05-07 2006-01-26 フェリング ベスローテン フェンノートシャップ Orally dispersible pharmaceutical formulation of desmopressin
US20060073190A1 (en) * 2004-09-30 2006-04-06 Carroll Thomas J Sealed, edible film strip packets and methods of making and using them
US20070020187A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070104783A1 (en) * 2001-02-28 2007-05-10 Axiomedic Ltd. Double-Layered Absorbable Solid Compositions for the Topical Treatment of Oral Mucosal Disorders
WO2008029386A3 (en) * 2006-09-05 2009-03-26 Dental Biotechnology Ltd Systems, methods and compositions for treatment and use of a palatal patch
JP2010501628A (en) * 2006-08-30 2010-01-21 ユーロ−セルティーク エス．エイ． Buprenorphine wafer for drug replacement therapy
USRE41408E1 (en) 1997-02-24 2010-06-29 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorpine
US20110124720A1 (en) * 2005-06-10 2011-05-26 Medical College Of Georgia Research Institute, Inc Compositions and methods for treating immune disorders
US20120045504A1 (en) * 2009-04-14 2012-02-23 Kathryn Whitehead oral drug devices and drug formulations
US8242131B2 (en) 2005-05-25 2012-08-14 Transcept Pharmaceuticals, Inc. Methods of treating middle-of-the-night insomnia
US8252809B2 (en) 2005-05-25 2012-08-28 Transcept Pharmaceuticals, Inc. Compositions for treating insomnia
US20130274352A1 (en) * 2009-04-14 2013-10-17 The Regents Of The University Of California Oral Drug Devices and Drug Formulations
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
US9572773B2 (en) 2010-04-26 2017-02-21 Novartis A.G. Layered drug delivery device

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
GB9815634D0 (en) * 1998-07-17 1998-09-16 Mars Uk Ltd Animal food composition
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
AU5907300A (en) 1999-07-02 2001-01-22 Procter & Gamble Company, The Compositions comprising organosiloxane resins for delivering xylitol to the oralcavity
US7803392B2 (en) * 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
EP2324821A1 (en) 2001-02-28 2011-05-25 Axiomedic Ltd. Oral care compositions
US6559180B2 (en) 2001-03-27 2003-05-06 Yuri Busiashvili Nitroglycerin-menthol potentiation for treatment of angina
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
GB2384986B (en) * 2002-02-12 2004-01-07 Reckitt Benckiser Healthcare Compositions for the treatment of disorders of the upper gastrointestinal tract
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20030194420A1 (en) * 2002-04-11 2003-10-16 Richard Holl Process for loading a drug delivery device
US7328706B2 (en) 2002-05-06 2008-02-12 Dynamic Mouth Devices Llc Therapeutic and protective dental device useful as an intra-oral delivery system
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US20040028744A1 (en) * 2002-06-17 2004-02-12 Sauwaluxana Tongaree Mucoadhesive composition
US8524200B2 (en) 2002-09-11 2013-09-03 The Procter & Gamble Company Tooth whitening products
US20070098648A1 (en) * 2002-11-05 2007-05-03 Haley Jeffrey T Treating mouth sores caused by dental braces with blobs of hydrophilic gums
MXPA05005243A (en) * 2002-11-14 2006-03-10 Innozen Inc Edible film for relief of cough or symptoms associated with pharyngitis.
US20040191302A1 (en) * 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
US6669929B1 (en) * 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
US20040156794A1 (en) * 2003-02-11 2004-08-12 Barkalow David G. Bioerodible and bioadhesive confectionery products and methods of making same
PT1473029E (en) * 2003-04-30 2005-05-31 Ferring Bv FORM OF SOLID DOSAGE UNDERSTANDING DESMOPRESSIN
US7094545B2 (en) 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US9278155B2 (en) * 2003-06-05 2016-03-08 3M Innovative Properties Company Adhesive compositions, articles incorporating same and methods of manufacture
US20040247654A1 (en) * 2003-06-05 2004-12-09 3M Innovative Properties Company Hydrophilic adhesives for delivery of herbal medicines
US7145125B2 (en) * 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
WO2005046363A2 (en) * 2003-11-07 2005-05-26 U.S. Smokeless Tobacco Company Tobacco compositions
ES2260563T3 (en) 2003-11-13 2006-11-01 Ferring B.V. BLISTER PACKAGE AND SOLID PHARMACEUTICAL FORM FOR IT.
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
ME01300B (en) * 2003-12-31 2013-12-20 Cima Labs Inc Generally linear effervescent oral fentanyl dosage form and methods of administering
AU2004311879B2 (en) * 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
US20050251072A1 (en) * 2004-05-10 2005-11-10 Patel Lalit A Buccal Cavity Washer
BRPI0514037B8 (en) * 2004-08-02 2021-05-25 Glaxo Group Ltd composition for oral care
EP1789057B1 (en) * 2004-08-30 2010-02-24 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
DE502005002524D1 (en) 2004-09-01 2008-02-21 Labtec Gmbh Atrium patch
DE102005003387A1 (en) * 2004-09-01 2006-03-02 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Plaster for administering active agents through body orifices, comprises adhesive and backing layers, both made of nonionic and anionic hydrocolloids in reverse ratios
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
BRPI0518191A (en) * 2004-10-15 2008-11-04 Seo Hong Yoo methods and compositions for reducing the toxicity of a pharmaceutical compound
EP1814558B1 (en) * 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
US20070048347A1 (en) 2005-08-26 2007-03-01 Laura Bardach Intra-oral device for treating obesity
US20070084471A1 (en) * 2005-10-14 2007-04-19 Salvatore Napoli Shock absorbing dental device
WO2007046890A1 (en) * 2005-10-14 2007-04-26 Effrx, Inc. Lozenge for treatment of dry mouth and related conditions
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US20070148213A1 (en) * 2005-12-22 2007-06-28 Sayed Ibrahim Film containing compositions
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US9289583B2 (en) * 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
WO2007095524A2 (en) * 2006-02-13 2007-08-23 Sonoma Holdings Llc Passive time released solute treatment
US8349120B2 (en) * 2006-03-07 2013-01-08 Ora Health Corporation Multi-layer patch made on a sheet and enclosed in a blister
EP1837020A1 (en) * 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
AU2007268240B2 (en) * 2006-05-23 2012-12-06 Orahealth Corporation Xylitol troches and methods of use
US20080044797A1 (en) * 2006-08-15 2008-02-21 Laura Bardach Inserts for use with oral appliances
US20100028447A1 (en) 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
WO2008120562A1 (en) * 2007-04-02 2008-10-09 Toyo Boseki Kabushiki Kaisha Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia
EP1980245A1 (en) * 2007-04-11 2008-10-15 Cephalon France Bilayer lyophilized pharmaceutical compositions and methods of making and using same
EP2316472A1 (en) * 2007-05-01 2011-05-04 Cephalon, Inc. Composition for transmucosal delivery of polypeptides
WO2009021106A1 (en) * 2007-08-07 2009-02-12 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
US20090053309A1 (en) * 2007-08-24 2009-02-26 Axiomedic Ltd., Gibraltar Adhesive compositions for the treatment of xerostomia
US9161909B2 (en) 2007-08-24 2015-10-20 Axiomedic Ltd. Adhesive compositions for the treatment of xerostomia
WO2009114192A2 (en) * 2008-03-14 2009-09-17 Cephalon, Inc. Enhanced transmucosal composition and dosage form
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
CA2724653A1 (en) 2008-05-21 2009-11-26 Ferring International Center S.A. Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
ES2929471T3 (en) 2009-06-18 2022-11-29 Acerus Pharmaceuticals Usa Llc Safe administration of desmopressin
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
TWI435733B (en) 2010-01-29 2014-05-01 Colgate Palmolive Co Oral care formulation for bad breath control
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
WO2014186410A1 (en) 2013-05-13 2014-11-20 NeuOra Microceuticals, LLC Long lasting breath mint
WO2014192918A1 (en) * 2013-05-31 2014-12-04 久光製薬株式会社 Oral cavity patch
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US10575976B2 (en) 2015-04-30 2020-03-03 Dynamic Mouth Devices, L.L.C. Method and apparatus for weight management utilizing an intra-oral device
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
US12150967B2 (en) 2018-08-18 2024-11-26 Seed Health, Inc. Methods and compositions for honey bee health

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4112066A (en) 1976-06-21 1978-09-05 Life Savers, Inc. Breath freshener composition and method
US4292028A (en) 1979-07-13 1981-09-29 Arthur Barr Cosmetic breath freshener and palate coolant composition and method of use
US4409202A (en) 1980-04-07 1983-10-11 Nabisco Brands, Inc. Breath freshener composition and method
US4303648A (en) 1980-04-07 1981-12-01 Life Savers, Inc. Breath freshener composition and method
US4597959A (en) 1982-04-30 1986-07-01 Arthur Barr Sustained release breath freshener, mouth and palate coolant wafer composition and method of use
US4740365A (en) 1984-04-09 1988-04-26 Toyo Boseki Kabushiki Kaisha Sustained-release preparation applicable to mucous membrane in oral cavity
US5008291A (en) 1987-08-26 1991-04-16 Ohio State University Research Foundation Method and composition for achieving chemotherapeutic activity
US4997852A (en) 1987-08-26 1991-03-05 Ohio State University Research Foundation Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
US5010107A (en) 1987-08-26 1991-04-23 Ohio State University Research Foundation Method and composition for achieving anticarcinogenic activity
US5431918A (en) 1992-10-30 1995-07-11 Soremartec S.A. Breath mint configuration
WO1995005416A2 (en) 1993-08-19 1995-02-23 Cygnus Therapeutic Systems Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE41408E1 (en) 1997-02-24 2010-06-29 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorpine
US9642850B2 (en) 1997-02-24 2017-05-09 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine
USRE41571E1 (en) 1997-02-24 2010-08-24 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine
USRE41489E1 (en) 1997-02-24 2010-08-10 Purdue Pharma L.P. Method of providing sustained analgesia with buprenorphine
US8980334B2 (en) * 2001-02-28 2015-03-17 Axiomedic Ltd. Double-layered absorbable solid compositions for the topical treatment of oral mucosal disorders
US20070104783A1 (en) * 2001-02-28 2007-05-10 Axiomedic Ltd. Double-Layered Absorbable Solid Compositions for the Topical Treatment of Oral Mucosal Disorders
JP2006502972A (en) * 2002-05-07 2006-01-26 フェリング ベスローテン フェンノートシャップ Orally dispersible pharmaceutical formulation of desmopressin
US7658945B2 (en) 2004-02-17 2010-02-09 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20050226925A1 (en) * 2004-02-17 2005-10-13 Transoral Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7682628B2 (en) 2004-02-17 2010-03-23 Transcept Pharmaceuticals, Inc. Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20060073190A1 (en) * 2004-09-30 2006-04-06 Carroll Thomas J Sealed, edible film strip packets and methods of making and using them
US8252809B2 (en) 2005-05-25 2012-08-28 Transcept Pharmaceuticals, Inc. Compositions for treating insomnia
US8242131B2 (en) 2005-05-25 2012-08-14 Transcept Pharmaceuticals, Inc. Methods of treating middle-of-the-night insomnia
US20110124720A1 (en) * 2005-06-10 2011-05-26 Medical College Of Georgia Research Institute, Inc Compositions and methods for treating immune disorders
US8574552B2 (en) 2005-07-22 2013-11-05 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US10258693B2 (en) 2005-07-22 2019-04-16 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US20070020187A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
US9446017B2 (en) 2005-08-11 2016-09-20 Augusta University Research Institute, Inc. Compositions and methods for treating herpes simplex virus
US9861628B2 (en) 2006-08-30 2018-01-09 Rhodes Pharmaceuticals L.P. Buprenorphine-wafer for drug substitution therapy
JP2010501628A (en) * 2006-08-30 2010-01-21 ユーロ−セルティーク エス．エイ． Buprenorphine wafer for drug replacement therapy
JP2013079265A (en) * 2006-08-30 2013-05-02 Euro-Celtique Sa Buprenorphine-wafer for drug substitution therapy
US9763931B2 (en) 2006-08-30 2017-09-19 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US9101625B2 (en) 2006-08-30 2015-08-11 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
US20100087470A1 (en) * 2006-08-30 2010-04-08 Euro-Celtique S.A. Buprenorphine-Wafer for Drug Substitution Therapy
US9370512B2 (en) 2006-08-30 2016-06-21 Purdue Pharma L.P. Buprenorphine-wafer for drug substitution therapy
WO2008029386A3 (en) * 2006-09-05 2009-03-26 Dental Biotechnology Ltd Systems, methods and compositions for treatment and use of a palatal patch
US20100092406A1 (en) * 2006-09-05 2010-04-15 Michael Moshe Perez-Davidi Systems, Methods, and Compositions for Treatment and Use of a Palatal Patch
US20150238435A1 (en) * 2009-04-14 2015-08-27 The Regents Of The University Of California Oral Drug Devices and Drug Formulations
US20130274352A1 (en) * 2009-04-14 2013-10-17 The Regents Of The University Of California Oral Drug Devices and Drug Formulations
US20120045504A1 (en) * 2009-04-14 2012-02-23 Kathryn Whitehead oral drug devices and drug formulations
US9572773B2 (en) 2010-04-26 2017-02-21 Novartis A.G. Layered drug delivery device

Also Published As

Publication number Publication date
AU764912B2 (en) 2003-09-04
CA2333156A1 (en) 2000-10-12
US6210699B1 (en) 2001-04-03
EP1089686A1 (en) 2001-04-11
AU4178600A (en) 2000-10-23
WO2000059423A1 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
US6210699B1 (en) Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
AU776525B2 (en) Compositions and methods for mucosal delivery
AU2002246916B2 (en) Bioadhesive cell foam film of sustained-release delivery
CA2169729C (en) Water-soluble pressure-sensitive mucoadhesive
KR101595139B1 (en) Gingival wafer
WO2007096906A2 (en) Novel buccoadhesive compositions and process of preparation thereof
JPH0729915B2 (en) Sheet-shaped oral patch
CN102427782A (en) Bilayer and monolayer dosage forms
JPH09194395A (en) Biologically adherent medicine composition for controlled release of active component
KR20030062139A (en) Oral mucoadhesive film
AU2002246916A1 (en) Bioadhesive cell foam film of sustained-release delivery
US20030219479A1 (en) Multi-layer mucoadhesive drug delivery device with bursting release layer
JP2004537566A (en) Taste masking composition
Pathan et al. Buccoadhesive drug delivery systems-extensive review on recent patents
JP2000178185A (en) Oral mucosa-attached sustained-release tablet
KR100342460B1 (en) Film-type Pharmaceutical Preparation for Oral Mucoadhesion and Process for Preparing the Same
JP2001002590A (en) Oral mucosa-attached sustained-release tablet
JPH0653659B2 (en) Mucoadhesive formulation
KR100302572B1 (en) Film-type oral mucoadhesive agent and its manufacturing method
Repka et al. Matrix-and reservoir-based transmucosal delivery systems: tailoring delivery solutions
JPS6347687B2 (en)

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION